Scientists

Scientists

For science to make the news in a rigorous and attractive way, good sources are needed. Because access to scientific knowledge is a citizen's right.

¿Qué me ofrece?

Help science make headlines with rigour and context. We’ll ask you for feedback on current events in your field and you can participate in the briefings we’ll organise. Need to prepare for an interview? Use our resources on science communication.

Icono
Cómo trabajamos

We’re on the lookout for controversial information about science and we will contact you for your analysis in your area. Do you want to be part of our sources? Contact us. We will not pass your contact details on to anyone else. You can find out more about how we work here.   

Título qué me ofrece
What we offer you
Título cómo trabajamos
How we work

A study involving 100,000 people shows that they all carry genetic variants that may influence their response to medicines

Pharmacogenomics studies how certain genes in a person – known as pharmacogenes – influence their response to medicines and the way in which the body metabolises them. One of the obstacles to its widespread adoption is the lack of diversity in research, as there is a scarcity of genetic data on groups of African and non-European descent. Now, a study published in Science Translational Medicine has analysed genetic and medication data from a diverse group of nearly 100,000 Americans participating in the All of Us medical initiative. 100 per cent had at least one variant in one of the 16 pharmacogenes, and 24.4 per cent had taken a medicine whose effect would be affected by one of those variants.

0

A research shows that taking other measures into account alongside BMI helps to identify more cases of obesity

Body mass index (BMI), commonly used to diagnose obesity, does not take into account differences in body composition or the distribution of body fat, which can affect health risks. A study published in Nature, using data from more than 844,000 adults in China, the United Kingdom, the United States and Spain, finds that incorporating other measures such as waist circumference and the waist-to-height ratio allows for the identification of between 3.3 per cent and 7.4 per cent more cases of obesity. The research also assesses the distinction proposed in 2025 between clinical obesity – when it is already affecting the body’s functioning – and preclinical obesity – when it is not yet doing so – as the former is associated with a higher risk of death.

0

Some antidepressants may be more effective than others in the long term

A review published in The Lancet Psychiatry shows that some antidepressants, such as escitalopram and duloxetine, may be more effective than fluoxetine at helping people with depression to improve and to remain on treatment in the long term — typically for around six months. The study, which pooled the results of 115 randomised controlled trials on 21 antidepressants involving more than 30,000 people, is the first to compare the long-term efficacy — over more than 12 weeks — of different antidepressants.

 

0

Pep Canadell: “Had it not been for the war in Iran, carbon emissions from fossil fuels would have risen slightly this year”

To coincide with COP31, which is currently taking place in Antalya (Turkey), the journal Earth System Science Data has published a new edition of the Global Carbon Budget, which provides data and analysis on global trends and the main sources of carbon dioxide emissions. SMC Spain organised a briefing session with Pep Canadell, one of the report’s lead authors, who analysed the implications of this year’s expected decline in emissions from fossil fuel sources – one of the report’s main findings.

0

For the first time since the pandemic, carbon emissions from fossil fuels could fall this year

The most comprehensive report on the carbon dioxide (CO₂) balance, the Global Carbon Budget 2026, estimates that this year CO₂ emissions from fossil fuels could fall by 0.4 per cent compared with 2025, standing at around 38,200 million tonnes. According to the authors, this decline – the first since the Covid-19 pandemic – could be explained by the expansion of solar and wind power, and by the war in Iran. The report, published in the journal Earth System Science Data, notes that the growth of clean energy is not yet fast enough to achieve a lasting reduction in global CO2 emissions from fossil fuel sources. 

0

In some regions, global warming may already resemble a world with a 1.5 °C rise in temperature

El Acuerdo de París tiene como meta que la temperatura global no aumente más de 2 °C por encima de los niveles preindustriales y proseguir con los esfuerzos para limitarlo a 1,5 °C. Sin embargo, es posible que algunas regiones del mundo ya hayan experimentado entre el 90 y el 94 % del calentamiento previsto para cuando la media global alcance los 1,5 °C por encima de los niveles preindustriales, y entre el 65 % y el 76 % del previsto con un calentamiento de 2 °C. Es la conclusión de un estudio publicado en la revista Nature Climate Change, cuyos resultados sugieren que el calentamiento regional en 2025 fue estadísticamente indistinguible de los niveles previstos en un mundo 1,5 °C más cálido.

0

Results are presented from the unsuccessful first clinical trial that aimed to reduce cardiovascular risk by lowering lipoprotein(a) levels

The HORIZON trial was the first to evaluate the potential effect on cardiovascular risk of a drug—pelacarsen—that reduces lipoprotein(a) levels in the blood. While this approach had generated high expectations, it did not prove successful in this trial, which involved 8,000 patients who had already experienced cardiovascular events. The negative results, which Novartis previewed in a press release in September, are being presented in full on November 7 at the American Heart Association congress and are published in NEJM.

0

A method transforms wind turbine blades, which are difficult to recycle, into materials with industrial applications

The difficulties involved in recycling wind turbine blades at the end of their useful life pose a growing problem, as it is estimated that by 2050 more than 40 million tonnes of this waste could have accumulated worldwide. A study published in Chem Circularity presents a method for transforming them into graphene and silicon carbide through rapid heating at high temperatures. The researchers have incorporated the resulting materials into resins and found that they improve some of the resins’ mechanical and thermal properties. The process, which has been tested on a laboratory scale, could facilitate the reuse of discarded blades to manufacture new products.

 

0

Microplastics could be behind the change in the colour of the ocean in the Great Pacific Garbage Patch

The smallest microplastics — those less than 300 micrometres in diameter — are difficult to measure in the ocean, but their optical properties could make it possible to detect them from space. A study published in Communications Earth & Environment has analysed satellite data from 2002 to 2022 and observed that some areas of the Great Pacific Garbage Patch have become more bluish and greenish. Using simulations, the researchers have found that these changes are consistent with an increase in the concentration of microplastics in the water. The results suggest that the colour of the ocean could help detect this pollution from space, although direct measurements are needed to confirm the link.

0

Lipoprotein (a): what we know about the new hope for cardiovascular health and its publicised failure

Lipoprotein (a) is a particle that is very similar to, but distinct from, LDL, the ‘bad cholesterol’. Regarded as the hidden factor in cardiovascular risk, some scientific societies recommend that it be measured at least once in a person’s lifetime. The problem is that there are no treatments based on it to reduce the risk of heart attacks or strokes. This summer, the first clinical trial involving one of the drugs under investigation was completed and, contrary to expectations, the pharmaceutical company Novartis announced that the trial had failed: the reduction in lipoprotein (a) did not improve the participants’ health. The full results, which may call into question a long-accepted theory, will be presented on Saturday 7 November at the American Heart Association’s annual meeting.

0